The opportunistic human pathogen Enterococcus faecium overproduces the low-affinity PBP5. In clinical strains, mutations in PBP5 further reduce its acylation rate by ␤-lactams. Previous studies have reported that ceftaroline had poor inhibitory activity against ␤-lactam-resistant E. faecium strains. In this study, we show that ceftaroline exhibits killing activity against our laboratory-derived ampicillin-resistant E. faecium mutant that overproduces a wild-type PBP5 and that ceftaroline inactivates PBP5 much faster than benzylpenicillin and faster than ceftobiprole. ␤ -Lactam antibiotics (penicillins, cephalosporins, carbapenems, and monobactams) represent the most important group of drugs prescribed to treat bacterial infections. They form stable acyl-enzymes with their targets, the membrane-bound D, D-transpeptidases, which are essential enzymes in peptidoglycan biosynthesis. These proteins are usually referred to as penicillin-binding proteins (PBPs) (1-3). The presence or overproduction of loweraffinity PBPs is responsible for the resistance of Gram-positive cocci against ␤-lactam antibiotics. It is known that the opportunistic human pathogen Enterococcus faecium overproduces the low-affinity PBP5 and that mutations further reduce the acylation rate of PBP5 by altering its amino acid sequence (4, 5). Ceftaroline is a cephalosporin with broad-spectrum activity against Grampositive organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and many common Gram-negative bacteria except those producing extended-spectrum ␤-lactamase (ESBL) or AmpC ␤-lactamase (6-8). The Staphylococcus aureus low-affinity PBP2a is closely related to PBP5 (9). It is inhibited by ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, which was recently approved by the U.S. Food and Drug Administration (FDA) for use in adult patients with acute bacterial skin and skinstructure infections and community-acquired bacterial pneumonia and more recently approved by the European Medicines Agency (EMA) for similar indications (10, 11). Previous studies have reported that ceftaroline had poor inhibitory activity against ␤-lactam-resistant E. faecium strains, all of which were expected to possess a PBP5 protein (6, 12) . To better understand these differences, we have characterized the interaction between a wild-type form of PBP5 and ceftaroline.
fractions. MICs of D63 (A) and D63r (B) for ceftaroline were 0.25 mg/liter and 2 mg/liter, respectively. The surviving bacteria were counted after 0, 4, and 24 h of incubation at 37°C by subculturing serial dilutions (at least 10-fold, to minimize drug carryover). For all data, the standard deviations were below 10% of the mean. ceftaroline ( Fig. 2 and Table 1 ) revealed that at twice the MIC values, all high-molecular-mass PBPs were inhibited by the antibiotic ( Fig. 2 ) and that the low-molecular-mass PBP6, a D, D-carboxypeptidase (16), was not affected. This inhibition pattern is completely different from that obtained with benzylpenicillin, for which PBP5 is the most resistant PBP (17) . The IC 50 s for ceftaroline on PBP5 were 1.40 Ϯ 0.09 mg/liter and 0.7 mg/liter when determined with membrane preparations and the purified sPBP5, respectively. The kinetic parameters governing the acylation of PBP5 by ceftaroline were determined by using the sPBP5 (a soluble PBP5 from which the N-terminal membrane anchoring peptide was removed), which was overproduced and purified as previously described, except that the molecular sieve step was eliminated (18) . The kinetics model used has been described previously (17) . On the basis of the data shown in Fig. 3 , the secondorder rate constant k ϩ2 /K for ceftaroline was 950 Ϯ 70 M Ϫ1 s Ϫ1 , i.e., 50 to 100 times higher than the value reported for benzylpenicillin (15 to 24 M Ϫ1 s Ϫ1 ), which indicates that ceftaroline inactivates sPBP5 much faster than benzylpenicillin (5) and faster than ceftobiprole, another anti-MRSA cephalosporin (k ϩ2 /K ϭ 110 Ϯ 10 M Ϫ1 s Ϫ1 [13] ). While the inhibitory activity of ceftaroline for E. faecium PBP5 is significant, the k ϩ2 /K rate constant for sPBP5 is 15 to 25 times lower than those determined for MRSA PBP2a (23,600 Ϯ 2,000 M Ϫ1 s Ϫ1 [unpublished data]) produced and purified in our laboratory (19) and for the penicillin-resistant Strep- tococcus pneumoniae PBP2x (12,600 M Ϫ1 s Ϫ1 ) (20) . The sPBP5-ceftaroline adduct was very stable. Indeed, no free enzyme could be detected after a 4-hour incubation of the isolated acyl-enzyme at 37°C.
We have shown that ceftaroline inactivates the low-affinity E. faecium PBP5 more efficiently than benzylpenicillin. It exhibits bacterial killing against our laboratory-derived ampicillin-resistant E. faecium mutant that overproduces the wild-type PBP5. Such a profile differs from those of most E. faecium clinical isolates, which were reported as resistant to all ␤-lactams, including ceftaroline (6) . Like other cephalosporins, ceftaroline is not indicated for treatment of enterococcal infections. It is likely that most E. faecium clinical isolates produce mutant PBP5 forms with reduced affinity. This suggests that simple overexpression of wildtype PBP5 is sufficient to moderately increase the MIC for ceftaroline but that amino acid substitutions in the protein are necessary to confer high-level resistance. Among the ␤-lactams tested to date, ceftaroline has the highest affinity for wild-type PBP5, which makes it a potentially useful tool for PBP5 studies.
